242 related articles for article (PubMed ID: 37787146)
61. Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: The Strong Heart Study.
Suchy-Dicey AM; Longstreth WT; Rhoads K; Umans J; Buchwald D; Grabowski T; Blennow K; Reiman E; Zetterberg H
Alzheimers Dement; 2024 Mar; 20(3):2072-2079. PubMed ID: 38215191
[TBL] [Abstract][Full Text] [Related]
62. Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.
Tideman P; Stomrud E; Leuzy A; Mattsson-Carlgren N; Palmqvist S; Hansson O;
Neurology; 2022 Apr; 98(15):e1525-e1533. PubMed ID: 35022305
[TBL] [Abstract][Full Text] [Related]
63. Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study.
Visser D; Verfaillie SCJ; Bosch I; Brouwer I; Tuncel H; Coomans EM; Rikken RM; Mastenbroek SE; Golla SSV; Barkhof F; van de Giessen E; van Berckel BNM; van der Flier WM; Ossenkoppele R
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2409-2419. PubMed ID: 36976303
[TBL] [Abstract][Full Text] [Related]
64. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
[TBL] [Abstract][Full Text] [Related]
65. Combined Effects of Synaptic and Axonal Integrity on Longitudinal Gray Matter Atrophy in Cognitively Unimpaired Adults.
Saloner R; Fonseca C; Paolillo EW; Asken BM; Djukic NA; Lee S; Nilsson J; Brinkmalm A; Blennow K; Zetterberg H; Kramer JH; Casaletto KB
Neurology; 2022 Nov; 99(20):e2285-e2293. PubMed ID: 36041868
[TBL] [Abstract][Full Text] [Related]
66. Protective effects of sleep duration and physical activity on cognitive performance are influenced by β-amyloid and brain volume but not tau burden among cognitively unimpaired older adults.
Aslanyan V; Ortega N; Fenton L; Harrison TM; Raman R; Mack WJ; Pa J
Neuroimage Clin; 2023; 39():103460. PubMed ID: 37379733
[TBL] [Abstract][Full Text] [Related]
67. APOE effects on regional tau in preclinical Alzheimer's disease.
Young CB; Johns E; Kennedy G; Belloy ME; Insel PS; Greicius MD; Sperling RA; Johnson KA; Poston KL; Mormino EC; ;
Mol Neurodegener; 2023 Jan; 18(1):1. PubMed ID: 36597122
[TBL] [Abstract][Full Text] [Related]
68. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.
Rabl M; Zullo L; Lewczuk P; Kornhuber J; Karikari TK; Blennow K; Zetterberg H; Bavato F; Quednow BB; Seifritz E; von Gunten A; Clark C; Popp J
Res Sq; 2024 Mar; ():. PubMed ID: 38562890
[TBL] [Abstract][Full Text] [Related]
69. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease.
Chatterjee P; Pedrini S; Stoops E; Goozee K; Villemagne VL; Asih PR; Verberk IMW; Dave P; Taddei K; Sohrabi HR; Zetterberg H; Blennow K; Teunissen CE; Vanderstichele HM; Martins RN
Transl Psychiatry; 2021 Jan; 11(1):27. PubMed ID: 33431793
[TBL] [Abstract][Full Text] [Related]
70. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
[TBL] [Abstract][Full Text] [Related]
71. Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression.
Pelkmans W; Shekari M; Brugulat-Serrat A; Sánchez-Benavides G; Minguillón C; Fauria K; Molinuevo JL; Grau-Rivera O; González Escalante A; Kollmorgen G; Carboni M; Ashton NJ; Zetterberg H; Blennow K; Suarez-Calvet M; Gispert JD;
Alzheimers Dement; 2024 Jan; 20(1):483-493. PubMed ID: 37690071
[TBL] [Abstract][Full Text] [Related]
72. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A
Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336
[TBL] [Abstract][Full Text] [Related]
73. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease.
Tanner JA; Iaccarino L; Edwards L; Asken BM; Gorno-Tempini ML; Kramer JH; Pham J; Perry DC; Possin K; Malpetti M; Mellinger T; Miller BL; Miller Z; Mundada NS; Rosen HJ; Soleimani-Meigooni DN; Strom A; La Joie R; Rabinovici GD
Brain; 2022 Dec; 145(12):4489-4505. PubMed ID: 35762829
[TBL] [Abstract][Full Text] [Related]
74. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
[TBL] [Abstract][Full Text] [Related]
75. Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status.
Bun S; Ito D; Tezuka T; Kubota M; Ueda R; Takahata K; Moriguchi S; Kurose S; Momota Y; Suzuki N; Morimoto A; Hoshino Y; Seki M; Mimura Y; Shikimoto R; Yamamoto Y; Hoshino T; Sato Y; Tabuchi H; Mimura M
Alzheimers Res Ther; 2023 Sep; 15(1):149. PubMed ID: 37667408
[TBL] [Abstract][Full Text] [Related]
76. Alzheimer's Disease and Cognitive Decline in Patients with Cardiovascular Diseases Along the Heart-Brain Axis.
Trieu C; van Harten AC; Leeuwis AE; Exalto LG; Hooghiemstra AM; Verberk IMW; Allaart CP; Brunner-La Rocca HP; Kappelle LJ; van Oostenbrugge RJ; Biessels GJ; Teunissen CE; van der Flier WM;
J Alzheimers Dis; 2024; 98(3):987-1000. PubMed ID: 38489178
[TBL] [Abstract][Full Text] [Related]
77. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
[TBL] [Abstract][Full Text] [Related]
78. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
79. Cortical microstructural associations with CSF amyloid and pTau.
Nir TM; Villalón-Reina JE; Salminen LE; Haddad E; Zheng H; Thomopoulos SI; Jack CR; Weiner MW; Thompson PM; Jahanshad N;
Mol Psychiatry; 2024 Feb; 29(2):257-268. PubMed ID: 38092890
[TBL] [Abstract][Full Text] [Related]
80. Elevated Tau PET Signal Depends on Abnormal Amyloid Levels and Correlates with Cognitive Impairment in Elderly Persons without Dementia.
Zhang RQ; Chen SD; Shen XN; Yang YX; Lu JY; Cui M; Zuo CT; Dong Q; Tan L; Yu JT;
J Alzheimers Dis; 2020; 78(1):395-404. PubMed ID: 32986669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
